{"classes":[{"categories":[{"measurements":[{"comment":"Data was not estimable for 1 participant as the values were below the level of detection","groupId":"OG000","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab"}],"paramType":"MEAN","populationDescription":"Safety Population. Only those participants with positive post-baseline antibody against belantamab mafodotin were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 153 weeks","title":"DE Phase: Concentration of ADAs Against Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"ng/mL"}